- Home
- ACT vs KYMR Comparison
ACT vs KYMR Comparison
Compare ACT & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | KYMR |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | 419 | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACT | KYMR |
|---|---|---|
| Price | $40.39 | $82.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 26 |
| Target Price | $42.67 | ★ $108.04 |
| AVG Volume (30 Days) | 263.9K | ★ 710.3K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 4.52 | N/A |
| Revenue | ★ $1,235,827,000.00 | $39,211,000.00 |
| Revenue This Year | $4.14 | $16.05 |
| Revenue Next Year | $2.41 | $4.79 |
| P/E Ratio | $9.09 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $31.28 | $19.45 |
| 52 Week High | $44.80 | $103.00 |
Technical Indicators
Market Signals| Indicator | ACT | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 47.15 |
| Support Level | $39.05 | $77.78 |
| Resistance Level | $41.12 | $95.90 |
| Average True Range (ATR) | 0.95 | 4.43 |
| MACD | -0.26 | -1.09 |
| Stochastic Oscillator | 2.01 | 14.60 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.